ChromaCode develops and provides easy to implement, cost-effective workflows for oncology and genomics, including reagent kits and cloud-based software.

ChromaCode

ChromaCode is a molecular diagnostics company with a bioinformatics focus and pedigree from Illumina, Google[x], Luminex, and Caltech. We leverage patented mathematical methods and algorithmic enhancements to enrich signal processing from the most popular life science instrumentation. We are using this to extract new information on biochemistry reactions and substantially increase the performance capabilities of today’s gold-standard biochemical assays at a very low cost. Visit us at www.chromacode.com.

XPRIZE

Moore Venture Partners

Windham Venture Partners

New Enterprise Associates

Northpond Ventures

Okapi Venture Capital

Caltech

Domain Associates

Pat Smerkers

Adjuvant Capital

Global Brain Corporation

ChromaCode, Inc.

Attending PMWC - Precision Medicine World Conference? Don’t miss the presentation by our Chief Business Officer, Padma Sundar, who is speaking about using our cutting edge #HDPCR assay.

ChromaCode’s unique ability to interrogate more than one target per color channel on digital PCR instruments enables applications that might otherwise require NGS. Featured example applications with fast turnaround time include (a) “rescue” assays for challenging samples (b) bespoke MRD assays and (c) donor-derived cell-free DNA testing of transplant patients.

The presentation is part of PMWC’s Showcase Track S2: Clinical Dx/Tools Track.
 
Learn more: https://lnkd.in/dEUqErYj

#PMWC24 #dPCR #genomics #PMWCintl

In this story in Technology Networks originally by University of California, Davis, Blood tests for circulating tumor DNA have been shown to detect cancers up to 18 months before clinical diagnosis via CT scans. 

This method of early detection is pivotal for developing targeted therapies, aligning with ChromaCode's mission to revolutionize healthcare through accessible genomic technologies. 

For more, please visit:  https://bit.ly/495d1Pd 

#HealthTech #HealthInnovation

🔬 Testing your genes for cancer risk is now more affordable, potentially saving lives. Innovation firms like ChromaCode, Inc. are spearheading efforts to democratize genetic screening, ensuring that individuals and families have access to crucial healthcare insights. 

This transformative approach, highlighted by NPR's Nell Greenfieldboyce, not only empowers individuals with knowledge about their genetics but also enables proactive measures for early detection and prevention. https://n.pr/45c2v7j 

#GeneticTesting #CancerAwareness #HealthcareInnovation

In the continuing series 'Conversations Life Science Leaders Aren't Having,' hear our Chairman & CEO Mark McDonough highlight ChromaCode, Inc.’s pivotal role in enhancing investor confidence.   

#Biotech #Innovation #JPM2024 #Genomics

In case you missed it: In an insightful Q&A with Medical Device & Technology  from last year, Mark McDonough, current Chairman & CEO of ChromaCode, Inc., delves into the revolutionary impact of HDPCR technology in genomics.  

McDonough highlights the technology's potential beyond lung cancer, including applications in transplant and tumor testing, and showcasing ChromaCode's commitment to advancing patient care through genomics.

For more, read here: https://bit.ly/3IoqkPY 

#HealthTech #Genomics #Innovation

Tune into the latest MedTech Insight podcast from Citeline featuring Mark McDonough, Chairman & CEO of ChromaCode, Inc., as he shares valuable insights into the future of genomic solutions.

Mark discusses the transformative potential of their technology, upcoming regulatory challenges, and what 2024 holds for the diagnostics industry. An enlightening listen for those interested in the cutting-edge of healthcare innovation.

To access the podcast episode, please visit: https://bit.ly/4bZ7ZXj 

#HealthcareInnovation #Cancer

First in Human, a podcast by Vial, features Mark McDonough, Chairman & CEO of ChromaCode discussing the transformative potential of HDPCR technology in early detection of disease. 

Mark shares insights into his professional journey—from military service to leading innovation in the genomics field. Discover how ChromaCode is overcoming industry challenges to introduce groundbreaking technologies, aiming to improve patient outcomes through faster, comprehensive genomic solutions. 

To read the transcript or download the podcast episode, visit: https://bit.ly/4376O43 

To listen to the episode on YouTube, please visit: https://bit.ly/42XBQeI 

#HealthcareInnovation #Genomics #Leadership

Watch Mark McDonough, Chairman and CEO of ChromaCode, Inc. engage in another insightful discussion with Jeff Harmon of 'Conversations Life Science Leaders Aren't Having' and Russo Partners, on growth discipline in today’s challenging environment. 

#Biotech #Innovation #JPM2024 #Genomics

Did you know our cloud analysis platform recently got an upgrade? ChromaCode Cloud 6.1 represents a significant leap forward in our commitment to enhancing our cutting-edge #genomics solutions.

The update includes:
☁ Extended instrument support
☁ Enhanced collaborative features
☁ Optimized for our #HDPCR #NSCLC RUO assay
☁ Continued regulatory certification with HITRUST Implemented, i1 certification

https://lnkd.in/ed7CK3y2 

#dPCR #Oncology #Innovation

#MeetTheTeam – Brett Brown, our VP of Finance and Administration, has over twenty years of experience in finance, corporate management, and human resources. 

He has worked in a broad range of industries and company sizes. His passion is helping companies with ground-breaking technology strategically expand their teams.

https://lnkd.in/ebXRC6Cz

#genetics #oncology #leadership #dPCR

Metric
Company Name	ChromaCode
Symbol
MSH ID	COM:CHROMACODE
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	US
Stage
Employee Count
Website	chromacode.com
LinkedIn	chromacode-inc.
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

CHRO

COM:CHROMACODE

ChromaCode

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue